Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q8TC44

UPID:
POC1B_HUMAN

ALTERNATIVE NAMES:
Pix1; Proteome of centriole protein 1B; WD repeat-containing protein 51B

ALTERNATIVE UPACC:
Q8TC44; G3V1X0

BACKGROUND:
The protein POC1B, also known as Proteome of centriole protein 1B, is integral to centriole assembly, ciliogenesis, and cell proliferation. It ensures centriole integrity and proper mitotic spindle formation in concert with POC1A. POC1B is crucial for primary cilia formation and retinal integrity, highlighting its significance in cellular structure and function.

THERAPEUTIC SIGNIFICANCE:
Given POC1B's critical role in Cone-rod dystrophy 20, a disease characterized by rapid vision loss, exploring its function offers a promising avenue for developing targeted therapies for retinal dystrophies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.